Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05278715

Modified CV Regimen in Optic Pathway Glioma

Clinical Study of Modified Carboplatin/vincristine Chemotherapy Regimen for Visual Function Protection in Children with Optic Pathway Gliomas

Sponsor: Beijing Sanbo Brain Hospital

Conditions Optic Glioma Pediatric Brain Tumor, Optic Nerve Glioma

Interventions Carboplatin Recombinant human endostatin Vincristine

Updated 6 times since 2022 Last updated: Oct 9, 2024 Started: Apr 13, 2022 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05278715, this PHASE2 trial focuses on Optic Glioma and Pediatric Brain Tumor, Optic Nerve Glioma and remains actively recruiting participants. Sponsored by Beijing Sanbo Brain Hospital, it has been updated 6 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Nov 2024 — Present [monthly]

Recruiting PHASE2
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Aug 2023 — Jul 2024 [monthly]

Recruiting PHASE2
Sep 2022 — Aug 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Apr 2022 — Sep 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Sanbo Brain Hospital

Data source: Beijing Sanbo Brain Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China